- Trials with a EudraCT protocol (249)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
249 result(s) found for: Allergic Reaction.
Displaying page 1 of 13.
EudraCT Number: 2015-000205-39 | Sponsor Protocol Number: A00426 | Start Date*: 2015-02-18 | |||||||||||
Sponsor Name:UCB, Inc. | |||||||||||||
Full Title: A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Year... | |||||||||||||
Medical condition: Allergic Rhinitis Chronic Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003458-28 | Sponsor Protocol Number: A00423 | Start Date*: 2015-02-18 | |||||||||||
Sponsor Name:UCB, Inc. | |||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With... | |||||||||||||
Medical condition: Allergic Rhinitis Chronic Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006551-39 | Sponsor Protocol Number: SP2007-31 | Start Date*: 2008-01-23 | |||||||||||
Sponsor Name:Resistentia Pharmaceuticals AB | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled dose selection study with two RP 01 formulations evaluating anti-IgE immunotherapy in allergic patients | |||||||||||||
Medical condition: Allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019160-37 | Sponsor Protocol Number: K-530 | Start Date*: 2010-06-29 | |||||||||||
Sponsor Name:Allergiklinikken | |||||||||||||
Full Title: Intralymfatisk specifik immunterapi - som ny behandlingsmetode til græspollenallergikere | |||||||||||||
Medical condition: Græspollen allergi | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-005060-18 | Sponsor Protocol Number: 2016AL002 | Start Date*: 2018-03-09 | ||||||||||||||||
Sponsor Name:Manchester University NHS Foundation Trust | ||||||||||||||||||
Full Title: The Role of Uric Acid Metabolism in Pathogenesis of Anaphylaxis: the Effect of Allopurinol on Experimentally-induced Allergic Reaction to Peanut in Peanut Allergic Adults- a randomised, double-blin... | ||||||||||||||||||
Medical condition: Determination of the Lowest Observed Adverse Event level dose (LOAEL)of peanut in individual suffering with peanut allergy, after treatment with allopurinol. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003019-39 | Sponsor Protocol Number: | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 study | |||||||||||||
Medical condition: Children aged 2-18 years (inclusive), some of whom will have asthma and/or food allergies. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002808-18 | Sponsor Protocol Number: AL0701rP | Start Date*: 2007-10-31 | ||||||||||||||||
Sponsor Name:ALLERGOPHARMA JOACHIM GANZER KG | ||||||||||||||||||
Full Title: A double-blind placebo controlled dose-response study for evaluation of safety and efficacy of immunotherapy with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)... | ||||||||||||||||||
Medical condition: ICD classification code: J45.0 and J30.1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001179-30 | Sponsor Protocol Number: OX914-001 | Start Date*: 2008-06-30 | |||||||||||
Sponsor Name:Orexo AB | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, cross-over, allergen challenge study to evaluate the efficacy, safety and tolerability of BLX-028914 in subjects with allergic rhinitis | |||||||||||||
Medical condition: Allergic rhinitis (LLT) Code 10001723 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001029-84 | Sponsor Protocol Number: AL0702rB | Start Date*: 2007-08-30 | ||||||||||||||||
Sponsor Name:Allergopharma Joachim Ganzer KG | ||||||||||||||||||
Full Title: A multicentre randomised, placebo-controlled, double-blind pivotal clinical trial for the evaluation of safety and efficacy of specific of immunotherapy with an aluminium hydroxide-adsorbed hypoall... | ||||||||||||||||||
Medical condition: ICD classification code: J45.0 and J30.1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000754-19 | Sponsor Protocol Number: AL1602av | Start Date*: 2017-11-09 | |||||||||||||||||||||||||||||||
Sponsor Name:Allergopharma GmbH & Co. KG | |||||||||||||||||||||||||||||||||
Full Title: A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxid... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without asthma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) ES (Completed) PL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005400-28 | Sponsor Protocol Number: AL1502AV | Start Date*: 2016-06-20 | |||||||||||||||||||||||||||||||
Sponsor Name:Allergopharma GmbH & Co. KG | |||||||||||||||||||||||||||||||||
Full Title: Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhin... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma during the birch pollen season | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002409-13 | Sponsor Protocol Number: AL1501AV | Start Date*: 2015-11-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Allergopharma GmbH & Co. KG | |||||||||||||||||||||||||||||||||
Full Title: A multicenter, randomized, open-label clinical trial to evaluate safety and tolerability of a year-round initiation of specific immunotherapy with an aluminum hydroxide adsorbed allergoid preparati... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-002881-42 | Sponsor Protocol Number: SL-351A | Start Date*: 2023-02-07 | ||||||||||||||||||||||||||
Sponsor Name:ROXALL Medizin GmbH | ||||||||||||||||||||||||||||
Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from grass pollen allergy | ||||||||||||||||||||||||||||
Medical condition: Patients with grass pollen-related allergic rhinitis/rhino-conjunctivitis (with well-controlled mild-to-moderate or without asthma) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000674-58 | Sponsor Protocol Number: AL1011av | Start Date*: 2011-07-28 | ||||||||||||||||
Sponsor Name:Allergopharma Joachim Ganzer KG | ||||||||||||||||||
Full Title: Double-blind, placebo controlled study to investigate the dose response of an allergoid preparation of Phleum pratense in adult patients with IgE mediated allergic Rhinitis / Rhinoconjunctivitis wi... | ||||||||||||||||||
Medical condition: ICD classification code: J 45.0 and J 30.1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006258-16 | Sponsor Protocol Number: AL0801rB | Start Date*: 2008-11-19 | ||||||||||||||||
Sponsor Name:ALLERGOPHARMA JOACHIM GANZER KG | ||||||||||||||||||
Full Title: A multicentre randomised placebo-controlled double-blind clinical trial for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant ... | ||||||||||||||||||
Medical condition: ICD classification code: J45.0 and J30.1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017828-54 | Sponsor Protocol Number: 1131/09 | Start Date*: 2011-03-28 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to -lactams. | |||||||||||||
Medical condition: allergy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004372-17 | Sponsor Protocol Number: TT-06 | Start Date*: 2021-04-20 | ||||||||||||||||
Sponsor Name:ALK-Abelló A/S | ||||||||||||||||||
Full Title: Efficacy and safety of the SQ tree sublingual immunotherapy tablet in children and adolescents (5 through 17 years of age) with moderate to severe allergic rhinitis and/or conjunctivitis induced by... | ||||||||||||||||||
Medical condition: Tree pollen induced allergic rhinitis and/or conjuctivitis. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) LT (Completed) HU (Completed) SK (Completed) PL (Completed) AT (Completed) DK (Completed) BE (Completed) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005301-22 | Sponsor Protocol Number: IPR110723 | Start Date*: 2008-02-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhini... | |||||||||||||
Medical condition: Seasonal allergic rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005340-12 | Sponsor Protocol Number: IPR101987 | Start Date*: 2006-03-23 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 14 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in an environmental exposition unit (Vienna Challenge Chamber) in ... | |||||||||||||
Medical condition: Seasonal Allergic Rhinitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020079-22 | Sponsor Protocol Number: DG40.08 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:STALLERGENES S.A. | |||||||||||||
Full Title: Determination of sensitivity and specificity of five solutions of allergen extract (5 grasses, birch, ragweed pollens and Dermatophagoides pteronyssinus and Dermatophagoides farinae mites) for diag... | |||||||||||||
Medical condition: Allergy to grass pollen Allergy to birch pollen Allergy to ragweed pollen Allergy to mites | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.